QPPV.COM KNOWLEDGE ASSESSMENT

EU Pharmacovigilance Inspection Findings: Recurring Patterns and What Inspectors Actually Test

Test your understanding of the concepts covered by EU Pharmacovigilance Inspection Findings: Recurring Patterns and What Inspectors Actually Test.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which evidence package would most convincingly demonstrate that a procedure is implemented rather than merely approved?

The signed SOP approval page and document number A training slide deck describing the procedure Relevant transaction records, training evidence, quality checks and performance data A management statement that the process is considered robust

Question 2 of 10 Which response best reflects the required distinction between published findings and illustrative scenarios?

Any plausible scenario may be presented as an official regulatory finding Published findings should be attributed to authoritative sources, while constructed examples should be labelled illustrative Illustrative scenarios are more authoritative than annual inspection reports Regulatory attribution is unnecessary when the scenario is professionally plausible

Question 3 of 10 Which pre-inspection exercise most closely simulates an inspector's practical testing approach?

Reviewing the index of all current SOPs Preparing a presentation describing the pharmacovigilance organisation Reconstructing a real ICSR from receipt through submission, acknowledgement and reconciliation Confirming that all employees completed annual training

Question 4 of 10 An inspector finds one late ICSR and asks how the MAH assessed whether other cases were affected. What capability is being tested?

The ability to defend the employee's individual performance The ability to determine the historical scope and affected population of a control failure The ability to revise the PSMF immediately The ability to classify every deviation as major

Question 5 of 10 What does operationally meaningful QPPV involvement look like during inspection review?

The QPPV signs the PSMF but receives no performance or escalation information The QPPV reviews significant issues, receives escalations and participates in governance and CAPA oversight The QPPV delegates all oversight to vendors and reviews only final inspection responses The QPPV attends the inspection opening meeting but has no role in remediation

Question 6 of 10 An inspector selects a real ICSR and asks which SOP, training, database control and quality check governed its processing. What inspection concept is primarily being applied?

Product-specific benefit-risk evaluation End-to-end traceability through the pharmacovigilance system Replacement of the PSMF by case-processing records Assessment of national marketing authorisation procedures

Question 7 of 10 Which sequence best represents the three-layer inspection test described in the article?

Requirement understood, process controlled, effective operation evidenced SOP approved, inspection room prepared, management notified Case received, case coded, case submitted Audit completed, CAPA opened, PSMF updated

Question 8 of 10 Which factor can explain why superficially similar deficiencies receive different regulatory attention?

The number of pages in the relevant SOP The inspector's preferred document format Differences in patient-safety impact, duration, scope, recurrence and detectability Whether the deficiency was discussed during a management meeting

Question 9 of 10 Which statement best describes effectiveness verification for a CAPA?

Completion of the planned action is sufficient evidence Effectiveness should be assessed using evidence that directly measures the failed control Effectiveness can be demonstrated solely by management approval Effectiveness testing is unnecessary when the CAPA is preventive

Question 10 of 10 An MAH has a case-processing delay, no KPI signal, no vendor escalation and no QPPV notification. What is the most appropriate interpretation?

It is solely a case-processor performance issue It may represent a cross-functional system weakness involving processing, monitoring, vendor oversight and governance It is not relevant unless more than one case was delayed It can be closed once the delayed case is submitted

QPPV.com

EU Pharmacovigilance Inspection Findings: Recurring Patterns and What Inspectors Actually Test

Cookie Settings